摘要
目的探讨脑胶质瘤患者组织中原癌基因c-erbB-2、乳腺癌耐药相关蛋白(BCRP)的表达及临床意义。方法选择2016年6月年至2017年8月在我院手术切除的脑胶质瘤标本62例作为观察组,另选同期颅脑外伤的正常脑组织12例为对照组。应用免疫组织化学SP法检测两组标本中的c-erbB-2和BCRP的阳性率表达,分析与患者临床病理特征的关系。结果观察组c-erbB-2、BCRP阳性表达率分别为41.94%(26/62)和46.77%(29/62),均明显高于对照组;脑胶质瘤组织c-erbB-2、BCRP阳性率与患者病理分期、分化程度具有关联性,病理分期越高,c-erbB-2和BCRP阳性率越高;而分化程度越低,c-erbB-2和BCRP阳性表达率越高,差异均有统计学意义(P<0.05)。结论脑胶质瘤组织中c-erbB-2和BCRP均呈高表达,其表达水平与患者病理分期呈正相关。
Objective To investigate the expression and clinical significance of proto oncogene c-erbB-2 and breast cancer resistance associated protein （BCRP） in patients with glioma. Methods 62 cases with glioma excised in our hospital from June 2016 to August 2017 were selected as observation group, and 12 cases with normal brain tissue in the same period of brain trauma were used as control group. Immunohi stochemical SP method was used to detect the positive rate of c-erbB-2, BCRP and expression in two groups of specimens, and to analyze their relationship with clinicopathological characteristics. Results The positive expression rates of c-erbB-2 and BCRP in observation group were 41. 94% （26/62）and 46. 77% （29/62）, which were significantly higher than those in control group. The positive rate of c-erbB-2 and BCRP in glioma tissues was related to the pathological stages and differentiation of the tumor. Higher pathological stages was related to higher positive rate of c-erbB-2 and BCRP. And the lower degree of differentiation was relative to the higher positive expression rate of c-erbB-2 and BCRP （ P 〈 0.05. Conclusion C-erbB-2 and BCRP are highly expressed in glioma tissues, and their expression levels are positively correlated with their pathological grades.
作者
张晶晶
杜鹏
逯霞
栾新平
木依提.阿不里米提
ZHANG Jing-jing;DU Peng;LU Xia;LUAN Xin-ping;Muyiti · Abulimiti(Department of Neurosurgery,the Second Affiliated Hospital of Xinjiang Medical University,Urumqi 830063,China)
出处
《标记免疫分析与临床》
CAS
2018年第8期1114-1116,1121,共4页
Labeled Immunoassays and Clinical Medicine
基金
新疆维吾尔自治区科技厅自然科学基金(编号:2017D01c247)
